Retention in opioid substitution treatment: A major predictor of long-term virological success for hiv-infected injection drug users receiving antiretroviral treatment

Clinical Infectious Diseases

Volumn 49, Issue 9, 2009, Pages 1433-1440

  Roux, Perrine ^a,b,c   Carrieri, M Patrizia ^a,b,c   Cohen, Julien ^a,b,c   Ravaux, Isabelle ^d   Poizot Martin, Isabelle ^e   Dellamonica, Pierre ^f   Spire, Bruno ^a,b,c  

^a OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Laboratoire Lagrange   (France)

^d Service des Maladies Infectieuses   (France)

^e HÔPITAL SAINTE MARGUERITE   (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BUPRENORPHINE; METHADONE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BUPRENORPHINE; FEMALE; HIV INFECTIONS; HUMANS; MALE; METHADONE; NARCOTICS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 72849125470     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/630209     Document Type: Article

References (39)

1. Carrieri MP, Moatti JP, Vlahov D, Obadia Y, Reynaud-Maurupt C, Chesney M. Access to antiretroviral treatment among French HIVinfected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Community Health 1999; 53: 4-8. (Pubitemid 29012343)
2. Carrieri MP, Chesney MA, Spire B, et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int J Behav Med 2003; 10:1-14. (Pubitemid 36378135)
3. Wood E, Montaner JS, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1-infected injection drug users. CMAJ 2003; 169:656-661 (Pubitemid 37266973)
4. Lawrinson P, Ali R, Buavirat A, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction 2008; 103:1484-1492
5. Essential Medicines. WHO Model List. 14th ed. (revised March 2005). Available at: http://archives.who.int/eml/expcom/expcom15/others/a87017-eng.pdf. Accessed 11 September 2009.
6. Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy 2007; 18:262-270 (Pubitemid 47126278)
7. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J; Manif 2000 study group. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. AIDS 2000; 14:151-155.
8. Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. Longterm immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14:959-969 (Pubitemid 30336056) (Pubitemid 30336056)
9. Tyndall MW, McNally M, Lai C, et al. Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes. Int J Drug Policy 2007; 18:281-287 (Pubitemid 47126277)
10. Duran S, Solas C, Spire B, et al. Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy? A comparison between patients self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS 2001; 15:1075-1077
11. Messiah A, Loundou AD, Maslin V, Lacarelle B, Moatti JP. Physician recognition of active drug use in HIV-infected patients is lower than validity of patients self-reported drug use. J Pain Symptom Manage 2001; 21:103-112 (Pubitemid 32156940)
12. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12:255-266
13. Roux P, Carrieri MP, Villes V, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 2008; 103:1828-1836.
14. Fuhrer R, Rouillon F, Lellouch J. Diagnostic reliability among French psychiatrists using DSM-III criteria. Acta Psychiatr Scand 1986; 73:12-16 (Pubitemid 16123875)
15. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measure 1977; 3:385-491.
16. Carlin JB, Wolfe R, Coffey C, Patton GC. Analysis of binary outcomes in longitudinal studies using weighted estimating equations and discrete- time survival methods: prevalence and incidence of smoking in an adolescent cohort. Stat Med 1999; 18:2655-2679 (Pubitemid 29465603) (Pubitemid 29465603)
17. Carrieri MP, Raffi F, Lewden C, et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther 2003; 8:585-594 (Pubitemid 38057104)
18. Grabar S, Le Moing V, Goujard C, et al. Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. J Acquir Immune Defic Syndr 2005; 39:284-292 (Pubitemid 40923207) (Pubitemid 40923207)
19. Pai NP, Lawrence J, Reingold AL, Tulsky JP. Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults. Cochrane Database Syst Rev 2006; 3:CD006148.
20. Braithwaite RS, Roberts MS, Goetz MB, et al. Do benefits of earlier antiretroviral treatment initiation outweigh harms for individuals at risk for poor adherence? Clin Infect Dis 2009; 48:822-826
21. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998; 280:78-86.
22. Chaisson RE, Keruly JC, Moore RD. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. JAMA 2000; 284:3128-3129
23. Turner BJ, Laine C, Yang CP, Hauck WW. Effects of long-term, medically supervised, drug-free treatment and methadone maintenance treatment on drug users emergency department use and hospitalization. Clin Infect Dis 2003; 37(Suppl 5):S457-63.
24. Bell J, Burrell T, Indig D, Gilmour S. Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002. Drug Alcohol Depend 2006; 81:55-61.
25. Cooper HL, Brady JE, Ciccarone D, Tempalski B, Gostnell K, Friedman SR. Nationwide increase in the number of hospitalizations for illicit injection drug use-related infective endocarditis. Clin Infect Dis 2007; 45:1200-1203 (Pubitemid 47580320) (Pubitemid 47580320)
26. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001; 27:251-259
27. Micallef JM, Macdonald V, Jauncey M, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 2007; 14:413-418 (Pubitemid 46744050) (Pubitemid 46744050)
28. Day JH, Grant AD, Fielding KL, et al. Does tuberculosis increase HIV load? J Infect Dis 2004; 190:1677-1684
29. Jones LE, Perelson AS. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART. Bull Math Biol 2005; 67:1227-1251
30. Gossop M, Marsden J, Stewart D, Treacy S. Reduced injection risk and sexual risk behaviours after drug misuse treatment: results from the National Treatment Outcome Research Study. AIDS Care 2002; 14: 77-93. (Pubitemid 34095168) (Pubitemid 34095168)
31. Dalmau J, Puertas MC, Azuara M, et al. Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection. Clin Infect Dis 2009; 48:229-238
32. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphinemaintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; 2:CD002207.
33. Feroni I, Peretti-Watel P, Masut A, Coudert C, Paraponaris A, Obadia Y. French general practitioners prescribing high-dosage buprenorphine maintenance treatment: is the existing training (good) enough? Addict Behav 2005; 30:187-191 (Pubitemid 39550450)
34. Barrau K, Thirion X, Micallef J, Chuniaud-Louche C, Bellemin B, San Marco JL. Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction 2001; 96:1433-1441 (Pubitemid 32977082) (Pubitemid 32977082)
35. Keen J, Oliver P, Mathers N. Methadone maintenance treatment can be provided in a primary care setting without increasing methadonerelated mortality: the Sheffield experience 1997-2000. Br J Gen Pract 2002; 52:387-389 (Pubitemid 34495495)
36. Smith S, Robinson J, Hollyer J, Bhatt R, Ash S, Shaunak S. Combiningspecialist and primary health care teams for HIV positive patients: retrospective and prospective studies. BMJ 1996; 312:416-420 (Pubitemid 26055358)
37. Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med 2005; 165:1769-1776 (Pubitemid 41138966) (Pubitemid 41138966)
38. Wagner G, Miller LG. Is the influence of social desirability on patients self-reported adherence overrated? J Acquir Immune Defic Syndr 2004; 35:203-204
39. Grignon M, Perronnin M, Lavis JN. Does free complementary health insurance help the poor to access health care? Evidence from France. Health Econ 2008; 17:203-219 (Pubitemid 351265995) (Pubitemid 351265995)